MX2019010573A - Method of treatment and device for the improved bioavailability of leukotriene receptor antagonists. - Google Patents

Method of treatment and device for the improved bioavailability of leukotriene receptor antagonists.

Info

Publication number
MX2019010573A
MX2019010573A MX2019010573A MX2019010573A MX2019010573A MX 2019010573 A MX2019010573 A MX 2019010573A MX 2019010573 A MX2019010573 A MX 2019010573A MX 2019010573 A MX2019010573 A MX 2019010573A MX 2019010573 A MX2019010573 A MX 2019010573A
Authority
MX
Mexico
Prior art keywords
montelukast
receptor antagonists
leukotriene receptor
treatment
improved bioavailability
Prior art date
Application number
MX2019010573A
Other languages
Spanish (es)
Inventor
G Zerbe Horst
Paiement Nadine
Obeid Rodolphe
W Conway Justin
Original Assignee
Intelgenx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intelgenx Corp filed Critical Intelgenx Corp
Publication of MX2019010573A publication Critical patent/MX2019010573A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed is a method of administration and device for the improved bioavailability of leukotriene receptor antagonists. This method and device involve an alkaline surface pH oral film dosage form designed to deliver leukotriene receptor antagonists, such as Montelukast, to the stomach in an amorphous precipitate suspended in aqueous medium. Also disclosed is a device and method for treating a disease, such as a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having an alkaline surface pH film layer and a safe and effective amount of Montelukast. The device is configured and formulated to predominantly achieve enteral delivery of the Montelukast. The method includes enterally delivering to a human or an animal in need of treatment, a safe and effective amount of Montelukast capable of crossing the blood-brain barrier.
MX2019010573A 2017-03-30 2018-03-29 Method of treatment and device for the improved bioavailability of leukotriene receptor antagonists. MX2019010573A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762478876P 2017-03-30 2017-03-30
PCT/CA2018/050389 WO2018176149A1 (en) 2017-03-30 2018-03-29 Method of treatment and device for the improved bioavailability of leukotriene receptor antagonists

Publications (1)

Publication Number Publication Date
MX2019010573A true MX2019010573A (en) 2019-10-24

Family

ID=63673863

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010573A MX2019010573A (en) 2017-03-30 2018-03-29 Method of treatment and device for the improved bioavailability of leukotriene receptor antagonists.

Country Status (9)

Country Link
EP (1) EP3600265A1 (en)
JP (1) JP2020512309A (en)
KR (1) KR20190128637A (en)
CN (1) CN110381931A (en)
AU (1) AU2018241534A1 (en)
BR (1) BR112019018388A2 (en)
CA (1) CA3056944A1 (en)
MX (1) MX2019010573A (en)
WO (1) WO2018176149A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3150213A1 (en) * 2018-09-14 2022-03-19 Intelgenx Corp. Method of treatment and device for the improved bio availability of montelukast, a leukotriene receptor antagonist
US11602504B2 (en) 2018-11-05 2023-03-14 Intelgenx Corp. Lipophilic active oral film formulation and method of making the same
US20210393611A1 (en) * 2018-11-05 2021-12-23 Intelgenx Corp. Lipophilic active oral film formulation and method of making the same
CN110496124A (en) * 2019-04-10 2019-11-26 中山大学附属第五医院 The compound for treating vascular malformation
CN114931578A (en) * 2022-05-16 2022-08-23 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) Application of montelukast in preparation of medicines for treating systemic lupus erythematosus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101074271B1 (en) * 2009-06-25 2011-10-17 (주)차바이오앤디오스텍 Fast dissolving oral dosage form containing steviosides as a taste masking agent
KR101077468B1 (en) * 2011-03-04 2011-11-07 (주)차바이오앤디오스텍 Stable orodispersible film formulation
BR112016008356B1 (en) * 2013-10-14 2022-12-13 Zim Laboratories Limited PROCESS/METHOD FOR PREPARING A WATER-SOLUBLE FILM OF RAPID ORAL DISSOLUTION AND THIN ORAL FILM
US9668970B2 (en) * 2013-12-02 2017-06-06 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
CN104784157B (en) * 2015-04-04 2018-06-26 齐鲁制药有限公司 A kind of montelukast oral membrane agent of stabilization

Also Published As

Publication number Publication date
EP3600265A1 (en) 2020-02-05
JP2020512309A (en) 2020-04-23
BR112019018388A2 (en) 2020-04-07
WO2018176149A1 (en) 2018-10-04
KR20190128637A (en) 2019-11-18
CN110381931A (en) 2019-10-25
CA3056944A1 (en) 2018-10-04
AU2018241534A1 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
MX2019010573A (en) Method of treatment and device for the improved bioavailability of leukotriene receptor antagonists.
MX2019004096A (en) Device and method of treating conditions associated with neuroinflammation.
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
PH12015501531B1 (en) Crenolanib for treating flt3 mutated proliferative disorders
BR112017006957A2 (en) pharmaceutical formulations for the oral release of peptide or protein type drugs
RU2015104537A (en) METHODS FOR TREATING STOMAL TUMORS OF THE GASTROINTESTINAL TRACT
BR112015018252A2 (en) stable fixed-dose aqueous pharmaceutical composition for nasal administration to a human, stable fixed-dose aqueous pharmaceutical composition for nasal administration for a human, stable suspension suitable for nasal administration to a human, method for treating rhinitis in a human human in need thereof, use of the pharmaceutical composition for nasal administration, method for releasing a pharmaceutical composition and kit
WO2015123576A3 (en) Targeted nanoparticle compositions and methods of their use to treat obesity
MY193694A (en) Membrane-adherent self-assembled systems for treatment of ocular disorders
HRP20211046T1 (en) Uses of benzimidazole derivative for nocturnal acid breakthrough
MX2018005715A (en) Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer.
MX2016009231A (en) Administration of tasimelteon under fasted conditions.
MX2019001467A (en) Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer.
SI2413933T1 (en) 2,4,6-trifluoro-n-(6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl)-benzamide for the treatment of migraine via the oral or intravenous route
TR201819662T4 (en) Orally dispersible film composition containing enalapril for the treatment of childhood hypertension.
CA3150213A1 (en) Method of treatment and device for the improved bio availability of montelukast, a leukotriene receptor antagonist
NZ716267A (en) A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
WO2015011653A9 (en) pH RESPONSIVE ORAL POLYMERIC PHARMACEUTICAL DOSAGE FORM
EA201890575A1 (en) COMPOSITIONS AND METHODS FOR THE SENSITIZATION OF PARASITES TO MEDICINES
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
WO2016193456A3 (en) Opioid receptor antagonist for use in treating patients with severe constipation
CY1120693T1 (en) COMBINATION OF A P33 MOVEMENT INHIBITOR WITH PACLITAXEL FOR USE IN THERAPY OR PREVENTION OF A HEAD AND CERVICAL CANCER
BR0313423A (en) Medicines for treatment against craving for a substance due to addiction
WO2018231176A3 (en) Combinations of diclofenac and h2 receptor antagonists for the treatment of pain and inflammation
EA201991384A1 (en) COMBINATIONS OF DICLOFENAC AND H2-RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN AND INFLAMMATION